MYC and melanoma: Abnormal activation of the Wnt/β-catenin signaling pathway and subsequent upregulation of β-catenin-driven downstream targets including c-Myc, survivin, cyclin D1, CDK4, and metalloproteinases has been detected in a wide range of tumor types, including melanoma [29].